Carol Berry

InterVenn Biosciences

InterVenn was born out of a simple, powerful belief: No one should ever be blindsided by disease. InterVenn has developed the first commercially available platform to exponentially improve the speed, scope, and scale of glycoproteomics. With our GlycoVision™ platform, powered by artificial intelligence (AI) and advanced machine learning (ML), we can achieve in minutes what would take a human operator months to achieve. In 2023, we will be launching GlycoKnow™ Colon, a laboratory-developed test that uses glycoproteomics to pinpoint precursors to colon cancer with a single blood draw. Our goal is to provide healthcare professionals with the power to work ahead of the onset of disease.